AnaptysBio, Inc. Selects Novel Anti-IL17 mAb with Best-in-Class Potential

SAN DIEGO--(BUSINESS WIRE)--AnaptysBio, a privately-held therapeutic antibody company, announced today the selection of a novel anti-IL17 monoclonal antibody (mAb) development candidate. The development candidate, also known as ANB004, meets stringent design goals required for differentiation against competitors on multiple key parameters.

Back to news